Pharmaceuticals and Healthcare Reports Japan Dyslipidemia Market

Japan Dyslipidemia Market Opportunities
and Outlook Report 2023
“. The launch of the proprotein convertase
subtilisin/kexin type 9 (PCSK9) biologics and the
cholesteryl ester transfer protein (CETP) inhibitors
will reshape the sales landscape of the dyslipidemia
market moving forward.”
Summary
Radiant Insights estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised
of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). Radiant Insights
expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over the ten year forecast
period, resulting in a market value of $37.9bn by 2023, of which 71% will be attributed to branded
drug sales ($26.9bn) and 29% to generic drug sales ($11.0bn). The current dyslipidemia market is
dominated by the statins, the revolutionary drugs that reduce low-density lipoprotein cholesterol
(LDL-C) and that have been proven to reduce the risk of cardiovascular events such as heart attack
and stroke. Other major lipid-modulating drugs, such as Zetia (ezetimibe), the fibrates, bile acid
sequestrants, omega-3 fish oil agents, and rare-disease therapies comprise the remainder of the
current dyslipidemia space. The launch of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
biologics and the cholesteryl ester transfer protein (CETP) inhibitors will reshape the sales
landscape of the dyslipidemia market moving forward.
Complete Report Available @ http://www.radiantinsights.com/research/dyslipidemia-
japan-drug-forecast-and-market-analysis-to-2023
In the 2013 base year, the only dyslipidemia drugs included in this forecast that were available in
Japan were the statins, ezetimibe, and the omega-3 fish oil agents. Of these, the statins contributed
Follow Us: